Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Emerging Biotech & Pharma Index: 36 More Cos.
Nov 24, 2008 01:40 AM
- Eleven Stocks to Consider for Short Selling
Aug 19, 2008 11:27 AM
- 2nd UPDATE: FDA Panel Unanimously Backs Lev Pharma Drug
May 02, 2008 03:31 PM
- UPDATE: FDA Panel Unanimously Backs Lev Pharma Drug
May 02, 2008 02:48 PM
- Dyax Corp. 1Q Loss Widens; Partners With Cubist On DX-88
Apr 24, 2008 08:37 AM
- Dyax To Get Royalty,Milestone Payments On Wyeth Xyntha
Feb 28, 2008 03:02 PM
- Dyax To Get Royalty,Milestone Payments On Wyeth Xyntha
Feb 28, 2008 03:02 PM
- Earnings Report: 02/27/2008
Feb 27, 2008 07:51 PM
- Buffett To The Rescue
Feb 12, 2008 09:43 AM
- Dyax, Sanofi-Aventis In License Pact For DX-2240 Antibody
Feb 12, 2008 12:46 AM
- FDA Accepts Filing and Grants Priority Review for DX-88 for Hereditary Angioedema
Nov 21, 2008 11:31 AM
- Dyax Corp. to Present at the Lazard Capital Markets Healthcare Conference
Nov 12, 2008 07:33 AM
- First-Ever Study Conducted Demonstrating Economic, Individual, and Societal Burden of Hereditary Angioedema
Nov 10, 2008 07:35 AM
- Dyax Corp. to Present at the Credit Suisse Healthcare Conference
Nov 06, 2008 07:38 AM
- Dyax Corp. to Present at the Rodman & Renshaw Healthcare Conference
Nov 05, 2008 07:32 AM
- Dyax Secures $50 Million Committed Equity Financing Facility
Oct 30, 2008 07:33 AM
- Dyax Corp. Announces Third Quarter 2008 Financial Results
Oct 22, 2008 07:32 AM
- Dyax Announces CEO Transition Plan
Oct 20, 2008 07:33 AM
- Dyax Corp. to Host Third Quarter 2008 Earnings Call and Webcast
Oct 15, 2008 07:33 AM
- Dyax Announces Completion of Biologics License Application for DX-88 for Hereditary Angioedema
Sep 24, 2008 07:33 AM
Analyst Ratings
|
|
Share Performance
|
Period
|
DYAX
|
Compare to S&P
|
| YTD |
-28.96 %
|
16.39 %
|
| 4 Weeks |
-22.39 %
|
-16.11 %
|
| 12 Weeks |
-43.97 %
|
-22.33 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 29.27 %
|
|
EPS Growth in Last Year: -11.54 %
|
|
Sales Growth in Last Quarter: 43.30 %
|
|
Sales Growth in Last Quarter: 107.33 %
|
|
|
